All Antibody articles
-
BusinessAntibody data manipulation extends to thousands of images across 15 suppliers
Sleuths discover widespread, systematic alteration of Western blots and other antibody data
-
PodcastThermo Fisher data manipulation & the shrinking chemical recycling industry
We discuss fabricated images in Thermo Fisher’s online catalogue. And, what barriers are preventing chemical plastic recycling from taking off?
-
BusinessThermo Fisher antibody data manipulation is a breach of trust, say researchers
Science sleuths say the problem is impacting research progress and Thermo’s response falls short
-
ResearchAI-designed antibodies target antigens with atomic precision
Epitope-binding proteins designed from scratch by generative AI model
-
ResearchNanobodies from alpacas and llamas could hold the key to a universal antivenom
Novel nanobody mix protects against 17 African snake species
-
BusinessNovartis spends on deals to offset patent losses
$12 billion Avidity acquisition is the latest pipeline-pumping transaction
-
BusinessEurope reconsiders Alzheimer’s antibody approval
Leqembi recommended for approval with restrictions to reduce side effect risk
-
BusinessPan-cancer approval shows huge potential for antibody–drug conjugates
Enhertu gains approval based on gene expression rather than tumour location
-
OpinionFrom one sinking ship to another?
Biogen abandoning Alzheimer’s antibody aducanumab is unusual, but hardly surprising, says Derek Lowe
-
BusinessPharmaceuticals roundup 2023
Regulatory and pricing reforms have topped industry agendas in 2023, while weight loss drugs surged and Covid-19 therapies waned
-
BusinessDanaher completes $5.7 billion Abcam acquisition
Deal proceeded despite significant opposition from founder and ex-chief Jonathan Milner
-
BusinessBiogen to cut 1000 more jobs by 2025
Biotech giant has also agreed to buy Reata Pharmaceuticals for $7.3 billion
-
BusinessAntibodies face Alzheimer’s reality
Companies are convincing regulators, but will doctors use them, and will providers pay for them?
-
BusinessRevolutionising RSV prevention
New vaccines and a long-acting antibody aim to protect older adults and babies from respiratory syncytial virus
-
NewsBillionaire professor donates ‘transformative’ sum to protein science institute
$210 million endowment from entrepreneur and Moderna investor Tim Springer will support ongoing research
-
BusinessUS supreme court confirms Amgen’s cholesterol antibody patents invalid
Decision could mean patent descriptions need to be even more detailed, and hence expensive
-
OpinionRegulators must follow their heads, not their hearts
The 2019 US approval of antibiotic Recarbrio seems not to have met the normally expected standards
-
BusinessMerck & Co to buy immunology specialist Prometheus
$10.8 billion cash deal give Merck rights to late-stage candidate for two inflammatory bowel conditions
-
BusinessSecond Alzheimer’s antibody approved in the US
Biogen–Eisai’s lecanemab can slow disease progression a little, but at significant cost and risk of side effects
-
BusinessAlzheimer’s antibody engenders anticipation
Tantalising press-released data on Biogen and Eisai’s lecanemab prompt questions without firm answers